Literature DB >> 10928475

Fibrinogen, fibrin and crosslinking in aging arterial thrombi.

R D McBane1, M A Ford, K Karnicki, M Stewart, W G Owen.   

Abstract

The assumption that fibrin and crosslinked fibrin impart irreversibility to arterial thrombi is explored with procedure developed for measuring changes in platelet function, morphology and fibrinogen metabolism in aging occlusive thrombi, in which the condition of stasis is imposed uniformly. Arterial thrombi containing autologous (111)In labeled platelets were generated in vivo by bilateral mechanical injury of porcine carotid arteries. Vessels containing the platelet-rich thrombi were harvested and incubated intact (37 degrees C) for intervals ranging from 30 min to 12 h. The isolated vessels were then bisected and agitated in culture medium containing tick anticoagulant and hirudin for 60 min. Disaggregated platelets were evaluated for yield (from (111)In radioactivity) viability (dense body ATP secretion) and morphology (electron microscopy). Western analysis of fibrin(ogen) in thrombus extracts was performed using anti-fibrinogen Bbeta- and gamma-chain monoclonal antibodies for thrombi at each time point. A stable recovery of nearly 50% of platelets was observed during 12 h of thrombus aging. As thrombi aged, viability of disaggregated platelets gradually decreased with platelet necrosis the predominant feature beyond 6 h. By western analysis of thrombus extracts, nearly 50% of fibrinogen was cleaved to fibrin and extensively crosslinked within 30 min of injury with no evidence of fibrinolysis. With the exception of a declining proportion of gamma-monomer, these features remain relatively constant during 12 h of thrombus maturation. It is concluded that neither fibrin nor crosslinked fibrin are dominant factors imparting cohesion within platelet thrombi. Furthermore, under conditions of complete arterial occlusion imposed by this experimental design, there is no evidence of endogenous fibrinolysis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10928475

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

1.  Lytic resistance of fibrin containing red blood cells.

Authors:  Nikolett Wohner; Péter Sótonyi; Raymund Machovich; László Szabó; Kiril Tenekedjiev; Marta M C G Silva; Colin Longstaff; Krasimir Kolev
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-07-07       Impact factor: 8.311

2.  Proteolytic resistance conferred to fibrinogen by von Willebrand factor.

Authors:  A Tanka-Salamon; K Kolev; R Machovich; E Komorowicz
Journal:  Thromb Haemost       Date:  2009-12-18       Impact factor: 5.249

3.  Contribution of neutrophil elastase to the lysis of obliterative thrombi in the context of their platelet and fibrin content.

Authors:  Gyöngyi Rábai; Nóra Szilágyi; Péter Sótonyi; Ilona Kovalszky; László Szabó; Raymund Machovich; Krasimir Kolev
Journal:  Thromb Res       Date:  2010-08       Impact factor: 3.944

4.  Propensity for young reticulated platelet recruitment into arterial thrombi.

Authors:  Robert D McBane; Catherine Gonzalez; David O Hodge; Waldemar E Wysokinski
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

5.  Hindered dissolution of fibrin formed under mechanical stress.

Authors:  I Varjú; P Sótonyi; R Machovich; L Szabó; K Tenekedjiev; M M C G Silva; C Longstaff; K Kolev
Journal:  J Thromb Haemost       Date:  2011-05       Impact factor: 5.824

6.  Suppressed catalytic efficiency of plasmin in the presence of long-chain fatty acids. Identification of kinetic parameters from continuous enzymatic assay with Monte Carlo simulation.

Authors:  Anna Tanka-Salamon; Kiril Tenekedjiev; Raymund Machovich; Krasimir Kolev
Journal:  FEBS J       Date:  2008-02-12       Impact factor: 5.542

7.  Free Fatty Acids Modulate Thrombin Mediated Fibrin Generation Resulting in Less Stable Clots.

Authors:  Anna Tanka-Salamon; Erzsébet Komorowicz; László Szabó; Kiril Tenekedjiev; Krasimir Kolev
Journal:  PLoS One       Date:  2016-12-12       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.